The Importance of Reagent Lot Registration in External Quality Assurance/Proficiency Testing Schemes

• Published in: Clinical chemistry (Baltimore, Md.) Md.), 2016-05, Vol.62 (5), p.708-715
• Main Authors: Stavelin, Anne, Riksheim, Berit Oddny, Christensen, Nina Gade, Sandberg, Sverre
• Format: Article
• Language: English
• Subjects: Albumins - analysis; Conflicts of interest; Creatinine - urine; Humans; Indicators and Reagents - standards; International Normalized Ratio; Laboratory Proficiency Testing; Medical laboratories; Methods; Patients; Performance evaluation; Point-of-Care Systems; Prothrombin Time; Quality assurance; Quality Assurance, Health Care; Quality control; Reagent Kits, Diagnostic; Response rates; Urine
• ISSN: 0009-9147; 1530-8561
• DOI: 10.1373/clinchem.2015.247585

Providers of external quality assurance (EQA)/proficiency testing schemes have traditionally focused on evaluation of measurement procedures and participant performance and little attention has been given to reagent lot variation. The aim of the present study was to show the importance of reagent lot registration and evaluation in EQA schemes. Results from the Noklus (Norwegian Quality Improvement of Primary Care Laboratories) urine albumin/creatinine ratio (ACR) and prothrombin time international normalized ratio (INR) point-of-care EQA schemes from 2009-2015 were used as examples in this study. The between-participant CV for Afinion ACR increased from 6%-7% to 11% in 3 consecutive surveys. This increase was caused by differences between albumin reagent lots that were also observed when fresh urine samples were used. For the INR scheme, the CoaguChek INR results increased with the production date of the reagent lots, with reagent lot medians increasing from 2.0 to 2.5 INR and from 2.7 to 3.3 INR (from the oldest to the newest reagent lot) for 2 control levels, respectively. These differences in lot medians were not observed when native patient samples were used. Presenting results from different reagent lots in EQA feedback reports can give helpful information to the participants that may explain their deviant EQA results. Information regarding whether the reagent lot differences found in the schemes can affect patient samples is important and should be communicated to the participants as well as to the manufacturers. EQA providers should consider registering and evaluating results from reagent lots.